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Ron (the receptor for Macrophage Stimulating Protein)
has never been implicated before in human malignancies
or in cell transformation. In this report we show that
Ron can acquire oncogenic potential by means of two
amino acid substitutions –D1232V and M1254T – aect-
ing highly conserved residues in the tyrosine kinase
domain. The same mutations in Kit and Ret have been
found associated with two human malignancies, masto-
cytosis and Multiple Endocrine Neoplasia type 2B
(MEN2B), respectively. Both mutations caused Ron-
mediated transformation of 3T3 fibroblasts and tumour
formation in nude mice. Moreover, cells transformed by
the oncogenic Ron mutants displayed high metastatic
potential. The Ron mutant receptors were constitutively
active and the catalytic eciency of the mutated kinase
was higher than that of wild-type Ron. Oncogenic Ron
mutants enhanced activation of the Ras/MAPK cascade
with respect to wild type Ron, without aecting the
JNK/SAPK pathway. Expression of Ron mutants in 3T3
fibroblasts led to dierent patterns of tyrosine-phos-
phorylated proteins. These data show that point
mutations altering catalytic properties and possibly
substrate specificity of the Ron kinase may force cells
toward tumorigenesis and metastasis.
Keywords: metastasis; ron; signal transduction; tumor-
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Introduction
Oncogenic activation of receptor tyrosine kinases
(RTKs) can occur through point mutations in the
extracellular, transmembrane, and catalytic domain,
resulting in ligand-independent activation. Examples of
activating mutations directly aecting the structure of
the TK domain are those found in the tyrosine kinases
Kit and Ret. The Kit mutation, which causes human
mast cell leukaemia (Furitsu et al., 1993; Tsujimura et
al., 1994) and human mastocytosis (Longley et al.,
1996), consists of the substitution of a conserved
aspartic acid residue located in subdomain VII of the
kinase with a neutral residue (Hanks et al., 1988). In
the case of the Ret receptor, a genetic alteration first
identified in patients with the inherited cancer
syndrome Multiple Endocrine Neoplasia type 2B
(MEN2B), converts a methionine residue in subdo-
main VIII of the kinase into threonine (Carlson et al.,
1994; Hofstra et al., 1994). Interestingly, the residues
mutated in Kit and Ret are highly conserved among
the receptor tyrosine kinases, but have dierent
identities in the cytosolic, non-receptor tyrosine
kinases (Hanks et al., 1988). It has been shown that
both mutations subvert the substrate specificity of the
respective kinases (Santoro et al., 1995; Piao and
Bernstein, 1996).
Ron is the receptor for MSP (Macrophage Stimulat-
ing Protein; Gaudino et al., 1994; Wang et al., 1994).
When activated, Ron exerts a wide spectrum of
biological activities on target cells of dierent origin:
epithelial cells (Collesi et al., 1996; Medico et al., 1996),
keratinocytes (Wang et al., 1995), neuroendocrine cells
(Gaudino et al., 1995; Willett et al., 1997), osteoclasts
(Kurihara et al., 1996), and haematopoietic cells
(Iwama et al., 1996; Banu et al., 1996). Recently it
has been demonstrated that Ron7/7 mice display a
deregulated inflammatory response (Correll et al.,
1997). Ron mediates mitogenic and apoptotic re-
sponses, as well as motility by signalling through a
multi-functional docking site, conserved in the evolu-
tionary related receptors Met and Sea (Ponzetto et al.,
1994; Iwama et al., 1996; Wang et al., 1996).
A number of RTKs are constitutively activated by
gene rearrangements which cause fusion of their kinase
domains with N-terminal dimerization motifs (for a
review see Rodrigues and Park, 1994). The Ron
homologue Met is converted into its transforming
counterpart Tpr-Met, by rearrangement with Tpr
sequences providing two leucine zippers (Cooper et
al., 1984; Park et al., 1986). We have previously shown
that a Tpr –Ron chimaera induces constitutive
activation of the Ron kinase but does not convert it
into an oncogene. This is most probably related to the
low intrinsic catalytic eciency of the Ron kinase
which results in lesser stimulation of MAPK/Erk 2
compared to Tpr –Met (Santoro et al., 1996).
We now report that introducing single point
mutations, modelled on Kit and Ret in subdomains
VII and VIII of the Ron kinase, results in activation of
its oncogenic potential and in triggering of a strong
metastatic program. These oncogenic substitutions
besides activating the Ron kinase in a constitutive
way also increase its catalytic eciency. The mutations
cause enhancement of MAPK (but not of JNK)
signalling and change the pattern of cellular protein
phosphorylation. These observations suggest that
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naturally occurring human tumours may harbour these
or similar mutations in the Ron gene.
Results
Mutations in the tyrosine kinase domain convert Ron in
a transforming gene
To explore the oncogenic potential of Ron, we inserted
in its tyrosine kinase domain single amino acid
substitutions (D1232V and M1254T) reproducing the
oncogenic mutations found in Kit (D814V) and Ret
(M918T), respectively in human mastocytosis and in
MEN2B. The substitutions were inserted by site-
directed mutagenesis in the Ron receptor and in the
constitutively active non-transforming Tpr-Ron chi-
maera (Figure 1). The mutant cDNAs were subcloned
into an expression vector containing the Major Late
Adenovirus promoter and tested for focus forming
activity in NIH3T3 fibroblasts.
While Ron and Tpr –Ron were totally ineective on
cell transformation, the D1232V and M1254T mutants
were highly transforming (Table 1). The M1254T
mutation induced a high number of foci (comparable
to Tpr –Met: 830 – 850/10 mg cDNA) whether it was
inserted in the context of Ron or Tpr –Ron.
Conversely, the D1232V mutation was less ecient in
transformation when inserted in the full-size Ron.
Cells expressing Ron mutants are tumorigenic in athymic
mice
To investigate the tumorigenicity of the transforming
Ron mutants, we used stable-transfected cell lines
expressing comparable levels of wild-type and mutant
Ron and Tpr –Ron proteins (Figure 2a). Western
blotting with phosphotyrosine antibodies revealed that
while in cells expressing wild-type Ron there was no
detectable autophosphorylation of the receptor, its
mutant counterparts and all Tpr –Ron chimaeras
were constitutively phosphorylated in vivo (Figure 2b).
These cells were injected subcutaneously in athymic
(nu/nu) mice. Control cells, as well as of non-
transformed cells expressing full-size Ron, did not
induce tumour formation, within an 8 week period of
observation (Table 1). In the case of Tpr –Ron (also
non-transforming), two mice out of four developed
small tumours with a long latency. In contrast,
injection of cells expressing Tpr –Ron mutants
D1232V and M1254T produced large tumours (about
20 mm in size) within 2 – 4 weeks in all animals tested.
Consistently with their transforming ability, also the
corresponding full-size Ron mutants (D1232V and
M1254T) led to tumour formation. However in this
case the latency was five weeks long. These data show
that the D1232V and M1254T Ron mutants, besides
being transforming, are also tumorigenic in vivo.
Point mutations increase catalytic eciency of the Ron
tyrosine kinase
As previously demonstrated, the catalytic eciency of
the Ron kinase, expressed as a ratio between Vmax and
KM, was inadequate to attain the signalling threshold
required for oncogenic transformation (Santoro et al.,
1996). To evaluate the catalytic eciency of Tpr –Ron
mutants, we determined their kinetic parameters, Vmax
(app) and KM (app), for phosphorylation of the
Figure 1 Schematic representation of the Ron receptor and the
Tpr –Ron chimaera. The oncogenic mutations in the activation
loop (shaded area) of the Ron tyrosine kinase domain are
indicated. TM, transmembrane domain; TK, tyrosine kinase
domain; LZip, two leucine zipper motifs
Table 1 Transforming activity of the Ron and Tpr –Ron mutants
Focus-forming No. of athymic
activity mice with tumour Onset of tumour
(foci/10 mg of formation/total mass Latency
cDNA cDNA)c number of micea (days) (weeks)
Vector
Ron
Ron D1232V
Ron M1254T
Tpr –Ron
Tpr –Ron D1232V
Tpr –Ron M1254T
41
41
390 – 405
785 – 810
41
845 – 855
800 – 820
0/4
0/4
4/4
4/4
2/4b
4/4
4/4
–
–
20 (3/4)
20 (4/4)
30 (2/4)
10 (2/4)
6 (4/4)
–
–
5
5
46b
4
2
a106 cells expressing constructs were subcutaneously inoculated into the posterior flank of female nu/nu mice.
The mice were every week checked for tumour solid formation at the site of inoculation. Animals in which
tumours did not form were observed for 8 weeks. bThese tumours did not reach the minimum size of 20 mm
at the end of the experiments. cTpr –Met yields 830 – 850 foci/10 mg cDNA in this assay
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exogenous substrate MBP (Myelin Basic Protein). As
shown in Figure 3, the catalytic eciencies of the
transforming mutants D1232V and M1254T were three
to four times higher, compared to that of Tpr –Ron.
Interestingly, the kinetic profiles of both Tpr –Ron
mutants revealed a shift to a KM for MBP four times
lower compared to that of Tpr –Ron, indicating an
increase in substrate anity (Figure 3). These data
show that, in correlation with the release of its
oncogenic potential, these mutations enhance the
catalytic eciency of the Ron tyrosine kinase
domain, and change its anity toward exogenous
substrates.
Phosphorylation of endogenous proteins by the dierent
oncogenic Ron mutants
To determine whether the dierences in the oncogenic
potential observed among wild-type and mutant Ron
proteins correlated with alterations in the phosphoryla-
tion of substrates in vivo, we compared patterns of
tyrosine phosphorylation between cell lines expressing
wild-type and mutant receptors.
Immunoprecipitation and Western blotting with
anti-phosphotyrosine antibodies on lysates made with
a buer containing non-ionic detergent, from cells
expressing the transforming mutants revealed two
specific phosphoproteins, with apparent molecular
masses of 100 kDa and 80 kDa. These proteins were
not phosphorylated in lysates of cells expressing wild-
type Tpr –Ron and Ron proteins (Figure 4a). This set
of phosphorylated proteins is reminiscent of two
phosphoproteins of similar molecular mass observed
in fibroblasts expressing the EGF receptor carrying the
MEN2B, Ret-type mutation (Pandit et al., 1996). A
panel of antibodies specific for known proteins in this
size range, namely GAP, GAB-1, Cbl, p85, failed to
react with these phosphorylated putative substrates
(data not shown).
To detect the association of Ron with specific
substrates, parallel experiments were performed by
immunoprecipitation with anti-Ron antibodies, fol-
lowed by Western blotting with anti-phosphotyrosine
antibodies. In this case lysis was performed in RIPA
buer. A tyrosine-phosphorylated protein of about
95 kDa was co-immunoprecipitated in these conditions
Figure 2 Expression and constitutive activation of the Ron and
Tpr –Ron mutant proteins. Western analysis on anti-Ron
immunoprecipitates from lysates (RIPA buer) of the NIH3T3
cells, expressing the wild-type and mutant proteins. Proteins were
separated in reducing conditions, transferred onto membranes
and probed with anti-Ron antibody (a) and anti-phosphotyrosine
antibody (b) as described in Materials and methods. The Ron
uncleaved precursor (pr 170) and the mature form (p150) are
indicated, as well as the Tpr –Ron chimaera (p60)
Figure 3 Catalytic eciency of Tpr –Ron and Tpr –Ron
mutants. Phosphorylation kinetic curves of wild-type Tpr –Ron
(*), Tpr –Ron D1232V (&), Tpr –Ron M1254T (*) in the
presence of increasing concentration of exogenous substrate
(MBP, Myelin Basic Protein). Plotted values are means of
triplicate determinations (error bars). The kinetic curves were
calculated by using a curve-fitting program for the Michaelis –
Menten equation (Grafit; Microsoft). The table indicates the
kinetic parameters (Vmax and KM) of the mutants respect to
MBP. Kinase assays were carried out on immunocomplexes, in
the presence of increasing concentrations of Myelin Basic Protein
(MBP) and of a constant concentration of ATP, as described in
the Materials and methods section. The kinase anity for MBP
(KM(app)) and the phosphorylation maximal rate (Vmax(app)) are
indicated. The ratio Vmax(app)/KM(app) represents the catalytic
eciency of the enzyme
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from cells expressing the Ron and Tpr –Ron oncogenic
mutants, but not in control cells and in cell expressing
full-size stimulated with MSP. Interestingly, these
experiments performed in RIPA buer reveal that the
Ron and Tpr –Ron mutants were constitutively
phosphorylated on tyrosine but at dierent levels
(Figure 4b).
MAPK/Erk 2 and JNK/SAPK signalling pathways are
dierently activated by the Ron oncogenic mutants
Cell transformation requires activation of the Ras/
MAPK signalling pathway as a mandatory step
(Cowley et al., 1994; Mansour et al., 1994), whereas
the role played by JNK/SAPK is still controversial
(Raitano et al., 1995; Rodrigues et al., 1997). To
examine whether the mutated Ron kinase activated
MAPK and/or JNK signalling, we expressed in HeLa
cells MAPK/Erk 2 or JNK/SAPK together with Ron,
the constitutive dimerized Tpr –Ron or their mutants.
MAPK/Erk 2-HA activity upon stimulation of
endogenous EGF receptor and JNK-HA activity in
response to anisomycin treatment were evaluated as
controls.
Tpr –Ron, which is constitutively active, induced a
twofold activation of MAPK/Erk 2 relative to Ron.
The D1232V mutant determined the largest increase in
MAPK/Erk 2 activity (fourfold as Tpr –Ron; sixfold as
Ron) over the corresponding non mutated form. The
M1254T mutation induced this activity to a lesser
extent (Figure 5a).
Tpr –Ron induced a fourfold increase of JNK
activity, compared to Ron. In contrast to the results
obtained with MAPK, the D1232V and M1254T
mutations did not over-stimulate JNK activity above
the level stimulated by wild-type Tpr –Ron. These
results indicate that the increased catalytic eciency of
the Ron tyrosine kinase conferred by these substitu-
tions has a selective eect on the stimulation of the
MAPK pathway, but does not enhance the JNK/
SAPK signalling pathway (Figure 5b).
Oncogenic activation of Ron confers a metastatic
phenotype
Since the introduction of activating mutations in the
kinase domain of Ron provoked a strong oncogenic
response in rodent fibroblasts, we investigated whether
these cells were capable to colonize lung tissues by
intravenous injection into the tail vein of athymic nu/nu
mice.
Four weeks after injection of Tpr –Ron D1232V and
M1254T expressing cells, mice were sacrificed because
they appeared cachectic and showed respiratory
distress. Similar results were obtained with the Ron
D1232V and M1254T mutants, but with longer
latencies (Table 2). Upon autopsy, lymph nodes were
increased in size and numerous large tumours were
evident in the lung of all the animals. These tumours
were particularly expanded in the case of M1254T
mutants, occupying almost the entire mass of the organ
(Figure 6b,c). Histopathological examination of the
excised sarcomas, showed the presence of abundant
vascular spaces and extensive microvascular vessels
formation. Typical cell whorl structures were observed,
compressing the normal alveolar tissue. These tumour
masses were characterized by elongated and spindle-
shaped cells with large nuclei containing condensed
chromatin (Figure 6d – f).
Discussion
Receptor tyrosine kinases (RTKs) become oncogenic
through a variety of mechanisms - including over-
expression, point mutations, partial deletions and gene
rearrangements resulting in constitutive activation of
the catalytic domain (Aaronson, 1991; Sawyers and
Denny, 1994). Oncogenic conversion has been reported
for the Ron homologues, Met and Sea. A rearranged
form of Sea has been identified as the transforming
Figure 4 Tyrosine phosphorylation of endogenous proteins in
NIH3T3 cells expressing the Ron and Tpr –Ron oncogenic
mutants. (a) Cell lysates, made in the presence of non-ionic
detergent from vanadate pre-treated cells, were analysed by
immunoprecipitation and Western blotting with monoclonal
anti-phosphotyrosine antibody as described in Materials and
methods. (b) Co-immunoprecipitation of substrates. Cell lysates
(RIPA buer), from vanadate pre-treated cells were immunopre-
cipitated with anti-Ron antibody and Western blotted with
phosphotyrosine antibody. Ron-expressing NIH3T3 cells (Ron)
were stimulated with culture media of cells transfected with an
empty vector or with a vector containing MSP cDNA (Ron +
MSP; Gaudino et al., 1994). Proteins extracted from cells
expressing wild-type Ron and its mutants (left panel) were
separated on 5% SDS–PAGE, while those from cells expressing
Tpr –Ron and its mutants (right panel) were separated on 8%
SDS–PAGE. Tyrosine-phosphorylated protein bands corre-
sponding to putative Ron oncogenic substrates are indicated on
the right
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component of the avian erythroblastosis S13 retrovirus
(Smith et al., 1989). The Met gene is activated by
constitutive dimerization, through rearrangement with
Tpr (Rodrigues and Park, 1993). To date, oncogenic
counterparts of Ron have not yet been identified and
no molecular alterations of the Ron receptor have been
associated to human malignancies.
In the aim of identifying mutations capable of
unmasking the Ron oncogenic potential, we focused
our attention on two residues (aspartate in subdomain
VII and methionine in subdomain VIII), highly
conserved among receptor tyrosine kinases, including
those of the Met family (Hanks and Quinn, 1991).
Substitution of these residues is responsible for the
oncogenic conversion of Kit and Ret receptors
(Kitayama et al., 1995; Santoro et al., 1995), and
causes subversion of substrate specificity (Songyang
and Cantley, 1995; Santoro et al., 1995, Piao and
Bernstein, 1996). Recently these activating mutations
have been found also in Met, in sporadic and
hereditary papillary renal carcinomas (Schmidt et al.,
1997; Jeers et al., 1997).
In this work we tested the eects of the D1232V
(‘Kit-type’) or the M1254T (‘Ret-type’) substitutions in
full-size Ron and in the constitutively active Tpr –Ron
chimaera. The latter was previously shown to be non-
transforming according to the canonical assays on
murine fibroblasts, such as focus forming assay,
anchorage-independent growth and low serum-cell
proliferation (Santoro et al., 1996). Tpr –Ron chi-
maeras containing either the ‘Kit-type’ or the ‘Ret-
type’ substitutions were capable of inducing the
formation of a number of foci of the same order of
magnitude as the well characterized Tpr –Met onco-
gene. The same results were also obtained with the
‘Ret-type’ full-size Ron. However only 50% of the foci
were induced by the ‘kit-type’ full-size Ron.
In vivo tumorigenesis revealed dierences between
the two Tpr –Ron mutants, related to the latency of
tumour appearance and growth. While ‘Kit-type’ Tpr –
Ron led to tumour formation in 4 weeks, a much
shorter latency of 2 weeks was observed for the Ret-
type mutant. This result is particularly striking since a
Figure 5 Eect of Ron oncogenic mutations on MAPK/Erk 2 and JNK/SAPK activity. HeLa cells were transfected with MAPK/Erk
2-HA or JNK-HA for the MAPK (a) or JNK/SAPK (b) assay, respectively, together with the empty vector or with vectors carrying
wild-type or mutated proteins, as indicated. Cells were treated with 100 ng/ml EGF for 15 min (a) or with 20 mg/ml anisomycin for
20 min (b) as controls. Kinase reactions and Western blot analysis were performed on anti-HA immunoprecipitates as described in
Materials and methods. Bar graph shows fold activation of MAPK (a) and JNK (b) activities in mutant transfected cells, relative to
cells transfected with wild type Ron. Data represent mean+s.d. of three independent experiments. Upper autoradiogram, showing
phosphorylated exogenous substrates MBP (a) orGST-Jun(79) (b) and lower Western blot, showing the amount of
immunoprecipitated HA-tagged eectors, are the results of representative experiments for MAPK and JNK assays, respectively
A
B
Table 2 Ron-mediated experimental lung colonization in athymic
mice
Cell line Mice with lung metastasis/ Latency
injected mice injecteda (weeks)
NIH 3T3
Ron
Ron/D1232V
Ron/M1254T
Tpr –Ron
Tpr –Ron/D1232V
Tpr –Ron/M1254T
0/4
0/4
4/4
4/4
0/4
4/4
4/4
–
–
9
6
–
5
3
aNumber of athymic mice with lung tumours/total number of mice.
106 cells were injected intravenously into the tail vein of athymic
nude mice, which were subsequently examined for lung colonization
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latency of 3 weeks had been observed for Tpr –Met in
similar experiments (Rong et al., 1994).
The above mutations are more ecient in in vivo
tumorigenesis when expressed in the constitutively
active Tpr –Ron chimaera, rather than in the full-size
Ron receptor, both in terms of onset of tumour mass
and latency. This may be due to the signal-enhancing
eect provided by the constitutive dimerization of the
kinase domain. However, the oncogenic potential of
the full-size receptor mutants is significant, since these
may more accurately reflect possible naturally occur-
ring mutations.
It has been demonstrated that transformation of
NIH3T3 cells through the expression of activated
oncogenes, like Ras, Rho or Met, is accompanied by
the acquisition of metastatic properties in athymic mice
(Muschel et al., 1985; Rong et al., 1994; Del Peso et al.,
1997). Here we show that oncogenic activation of Ron
confers to NIH3T3 cells a metastatic phenotype. This
means that mutated Ron can trigger all the events
necessary to exit from vascular and/or lymphatic
circulatory systems and to penetrate into the target
organs, as well as cell proliferation and angiogenesis,
required for colonization of the new site. Again, Tpr –
Ron mutants exert their eect earlier than the
corresponding Ron mutants.
Altogether these results demonstrate for the first
time that Ron has the potential to transform cells and
to elicit tumorigenic and metastatic programs.
RTKs mediate cell transformation when their
activity is permanently stimulated. The occurrence of
constitutively autophosphorylated receptor indicates
that the tyrosine kinase activity is blocked in a non-
inhibitory condition, responsible for continuous down-
stream signalling to the nucleus (Hubbard et al., 1994;
Mohammadi et al., 1996; Hubbard, 1997). Here we
show that Ron receptor mutants are constitutively
phosphorylated on tyrosine, as revealed by anti-
phosphotyrosine antibodies. Furthermore, the differ-
ence observed in the level of tyrosine phosphorylation
between mutants (being Ron M1254T more phos-
phorylated than Ron D1232V) correlates with their
distinct transforming capacities.
Previous results obtained by kinetic analysis showed
that the catalytic eciency of the Ron kinase is
inadequate to mediate transformation (Santoro et al.,
1996). The two mutations described here are very
eective in shifting the kinetic parameters (Vmax and
KM) of the Ron kinase, so that the catalytic eciency
can attain the threshold required for full transforma-
tion. Interestingly, the KM of the kinase for the MBP
substrate, widely used for measures of kinase activity,
is shifted toward significantly lower values for the
mutants, with respect to Tpr –Ron. This demonstrates
that the oncogenic mutations alter the anity of the
Ron kinase, at least for the MBP exogenous substrate.
It has been demonstrated that the oncogenic forms
of Kit and Ret kinases exert their function by altering
the fidelity of signalling, by subversion from receptor-
to cytosolic-specific substrates (Piao and Bernstein,
1996; Santoro et al., 1995; Songyang and Cantley,
1995). Introduction of the Ret/MEN2B oncogenic
mutation into the EGF receptor kinase enhanced its
transforming ability and produced the same shift of
Figure 6 Histopathology of Ron-induced lung sarcomas. (a) Normal lung. (b,c) Lungs from animals injected with Ron D1232V
and Ron M1254T mutants are characterized by a massive cell colonization. Scale bar: 8 mm. Lungs were paran-embedded,
sectioned, stained with hematoxylin and eosin, and photographed. Sarcomas compress the normal alveolar tissue (d), are highly
vascularized in appearance (e) and contain typical cell whorl structures (f). d and e,f were photographed at 610 and 633
respectively
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substrate specificity (Pandit et al., 1996). Our data
suggest that the D1232V and M1254T mutations alter
substrate specificity also in the Ron receptor. The
selective tyrosine phosphorylation of a co-immunopre-
cipitated 95 kDa protein and of the putative substrates
of 80 and 100 kDa in cells expressing oncogenic Ron
and Tpr –Ron, suggests that they may be positive
eectors of cell transformation. Despite the eorts to
characterize these putative substrates, their identity is
still elusive. The attempts to these proteins are not
recruited simply by functional (ligand-dependent) or
constitutive (Tpr –Ron) activation of the kinase, but
only upon structural alteration of the kinase by these
oncogenic mutations.
Activation of the Ras/MAPK pathway has been
shown to be required for transformation mediated by a
number of tyrosine kinases (Stacey et al., 1991). The
two Ron oncogenic mutations must activate MAPK/
Erk 2 activity above the threshold necessary for cell
transformation. Interestingly the ‘Ret-type’ mutation,
when inserted both in Ron and in Tpr –Ron, is less
active on this pathway, than the ‘Kit-type’ mutation,
despite its highest oncogenic potential. This suggests
that other pathways may be involved in producing the
biological eect.
It has been demonstrated recently that JNK
activation is essential for transformation by the Tpr –
Met oncogene (Rodrigues et al., 1997). Our data show
that non-transforming Tpr –Ron also activates the
same pathway, to an extent even greater than MAPK.
Surprisingly, the two oncogenic mutations seem not to
influence JNK activity. This suggests that their eects
may be mediated by alternative signalling due to the
shift in substrate specificity, rather than to the
potentiation of canonical pathways. To the best of
our knowledge no other reports exist on the role
played by these types of mutations on MAPK and
JNK signalling.
This work reveals for the first time the tumorigenic
and metastatic potential of Ron and suggests that
activating point mutations in the Ron gene may play a
role in the establishment of human cancers. The search
for these mutations should be pursued in tumours
derived from Ron expressing tissues.
Materials and methods
Molecular constructs
All the single point mutations were introduced by site-
directed mutagenesis using the Alter Sites In vitro
Mutagenesis System Kit (Promega Corp., Madison, WI).
The cDNAs encoding for Ron (Gaudino et al., 1994) and
Tpr –Ron (Santoro et al., 1996) were subcloned into the
pAlter vector (Promega Corp., Madison, WI) and
subjected to mutagenesis reaction. Mutations D1232V
and M1254T were generated on Ron cDNA, by using the
following oligonucleotides 5'-GCCCGCGTCATCCTGGA-
CAG-3' and 5'-TGAAGTGGACGGCGCTGG-3', respec-
tively. Mutations were confirmed by DNA sequencing with
T7 polymerase (Pharmacia, Uppsala, S) according to the
dideoxynucleotide methods (Sanger et al., 1977). All
constructs were inserted into the pMT2 eukaryotic
expression vector, under control of the Major Late
Adenovirus promoter, and transiently expressed in COS-1
cells, as well as in G418-selected NIH3T3 mouse embryo
fibroblasts.
Cell lines and experimental animals
NIH3T3 mouse fibroblasts, HeLa and COS-1 cells were
purchased from ATCC (American Type Culture Collec-
tion). Cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% foetal bovine serum
(GIBCO BRL Life Technologies, Inc., Gaithersburg,
MD) and maintained at 378C in a 5% CO2-humidified
atmosphere. NIH3T3 fibroblast stable cell lines expressing
comparable levels of Ron/Tpr – Ron mutants were
obtained by pools of cells isolated from foci of transforma-
tion. To establish cell lines expressing similar levels of the
corresponding non-transforming wild type counterparts,
G418-selection was used. Parallel cultures of the NIH3T3
cells stable transfected with the empty pSV2-neo vector
were also established as control cell lines. The transfectants
were obtained by co-transfection of each recombinant
plasmid cDNA with pSV2-neo plasmid (ratio 15 : 1) using
the calcium phosphate precipitation technique (CellPhect,
Pharmacia, Uppsala, S). The following selection was
performed in growth medium supplemented with 0.4 mg/
ml of G418-sulfate (geneticin; GIBCO –BRL Life Tech-
nologies, Inc., Gaithersburg, MD). After 2 weeks, the
neomycin resistant colonies were picked up and expanded
into cell lines. Stable cell cultures expressing the respective
recombinant proteins were selected by Western blot using
specific Ron C-terminal antisera (Gaudino et al., 1994).
The mice utilized were 6 weeks old female athymic nudes
(CD-1 nu BR) which were obtained from Charles River,
Italy. Animal care was provided in accordance with the
current national regulations regarding the protection of
animals used for experiments and for other scientific
purposes (Italian Ministry of Health, D.L.von. 116, 27/
01/1992).
Biochemical assays
Cells were washed twice with cold phosphate-buered
saline (PBS) and lysed with an ice-cold RIPA buer
containing 1 mM sodium orthovanadate and inhibitors of
proteases (aprotinin, 10 mg/ml; pepstatin, 10 mg/ml; leu-
peptin, 50 mg/ml; phenylmethanesulfonyl fluoride, 1 mM).
The cell lysates were cleared by centrifugation at 15 000 g
for 15 min at 48C; an equal amount (800 mg) of total
proteins from each cell lines, determined using the BCA
Protein Assay Reagent Kit (Pierce, Rockford, IL, USA),
were immunoprecipitated with stirring for 2 h at 48C with
the anti-Ron specific antisera absorbed to 40 ml of protein
A-Sepharose 4B packed beads (Pharmacia, Uppsala, S).
The immunocomplexes were washed twice with lysis buer
and proteins from immunoprecipitates were solubilized in
boiling Laemmli buer in reducing conditions. The
proteins were separated on 8% SDS – PAGE and trans-
ferred to nitro-cellulose filters (Hybond, Amersham, UK).
Filters were probed with the appropriate antibodies and
specific binding was detected by the enhanced chemilumi-
nescence system (ECL, Amersham, UK). Intracellular
substrates tyrosine phosphorylation was evaluated by
Western blotting as described above, on immunoprecipi-
tates using phosphotyrosine monoclonal antibodies from
UBI (Lake Placid, NY) or using anti-Ron specific antisera
(Gaudino et al., 1996). Quiescent NIH3T3 fibroblasts were
pre-treated with 1 mM sodium vanadate prior to cell
extraction, performed in two dierent conditions. For
anti-phosphotyrosine immunoprecipitates, cells were lysed
in a buer containing 10 mM PIPES pH 6.8, 100 mM NaCl,
5 mM MgCl2, 300 mM sucrose, 5 mM EGTA (DIM buer),
1% Triton X-100, 100 mM sodium orthovanadate, 10 mM
sodium pyrophosphate and inhibitors of proteases
(aprotinin, 10 mg/ml; pepstatin, 10 mg/ml; leupeptin,
50 mg/ml; phenylmethanesulfonyl fluoride, 1 mM). For
anti-Ron immunoprecipitates, cells were lysed in RIPA
buer, as described above.
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Transforming assays
The focus forming assay was performed on NIH3T3
fibroblasts (56105 cells) that were co-transfected with
10 mg of each recombinant plasmid and 0.8 mg of pSV2-
neo, using the calcium phosphate precipitation technique
(CellPhect, Pharmacia, Uppsala, S). Twenty-four hours
after DNA transfection the cultures were split at low cell
density into 100 mm dishes, and incubated in DMEM
medium supplemented with 5% foetal calf serum. The cell
cultures were maintained at confluence and screened for
foci formation 10 – 18 days later. Spontaneous formation of
foci was negligible. All the experiments were performed in
triplicate. To verify the eciency of transfection, a fraction
of cells were selected in G418-containing medium. Foci
derived cells and G418-resistant clones were established as
stable lines, to verify chimaeric protein expression.
Analysis of kinetic parameters
An equal amount (10 mg) of Tpr – Ron and relative mutant
cDNAs were transfected in COS-1 cells by the DNA-
calcium phosphate co-precipitation procedure. After 60 h
of transient transfection the confluent cell cultures were
placed on ice, washed twice with cold PBS, and solubilized
in 1 ml of ice-cold DIM buer containing 1% Triton X-
100, 100 mM sodium orthovanadate, and inhibitors of
proteases (aprotinin, 1 mg/ml; pepstatin, 50 mg/ml; leupep-
tin, 500 mg/ml; soybean trypsin inhibitor, 500 mg/ml;
phenylmethanesulfonyl fluoride, 1 mM). Cell lysates were
cleared by centrifugation at 48C for 15 min at 13 000 g.
The supernatants were immunoprecipitated with Sephar-
ose-protein A (70 ml of packed beads per ml of lysate) and
with the relative Ron antibody for 3 h at 48C with stirring.
To quantify the relative amounts of protein immunopreci-
pitated by the same antibody from dierent samples,
aliquots of immunocomplexes were analysed by Western
blotting. After immunoprecipitation beads were washed
two times with lysis buer and two times with the kinase
buer (KB: 25 mM HEPES-NaOH pH 7.4, 5 mM MnCl2,
100 mM DTT). Washed immunocomplexes were divided
into equal aliquots and used for the experiments. To
measure the catalytic eciency, the kinase reaction was
performed in 30 ml of reaction buer supplemented with
increasing concentrations of MBP exogenous substrate
(0.7, 1.4, 2.8, 5.6 mM) and of a constant concentration of
ATP (100 mM). ATP concentration was adjusted to the
specific activity (s.a.) of 0.5 – 0.6 mCi/mmol with
[g-32P]ATP (Amersham, UK). The range of ATP concen-
trations was determined by serial dilutions, maintaining the
specific activity unchanged. The standard reaction time for
exogenous substrate phosphorylation was 3 min at 48C
with continuous stirring, as determined by preliminary
time-course experiments. The reactions were stopped by
adding boiling Laemmli buer, and the eluted proteins
were separated on 15% SDS – PAGE followed by auto-
radiography at 7708C with intensifying screens. Phosphate
incorporation was estimated by scintillation counting of
the excised labelled bands in a Packard b-counter.
MAPK and JNK kinase assays
Subconfluent HeLa cells were co-transfected with
pcDNA3-HA-JNK (Coso et al., 1995) or pcDNA-HA-
MAPK/Erk 2 (Crespo et al., 1994) and the various cDNAs
of the Ron/Tpr – Ron mutants using the lipofectAMINE
method (GIBCO –BRL Life Technologies, Inc., Gaithers-
burg, MD) according to the protocol of the manufacturer.
Total amount of DNA was adjusted to 2.5 mg per 35 mm
plates. Twenty-four hours after transfection the cells were
starved 16 h in serum-free medium and UV/stress-free
conditions. The cells were then left untreated. As control
cells were stimulated with 100 ng/ml EGF for 15 min or
with 20 mg/ml anisomycin for 20 min. Cells were washed
with ice-cold PBS, and lysed at 48C in a buer containing
25 mM HEPES (pH 7.5), 0.3 M NaCl 1.5 mM MgCl2
0.2 mM EDTA, 0.5 mM DTT, 0.5% sodium deoxycholate,
1% Triton X-100, 0.1% SDS, 20 mM b-glycerophosphate,
25 mM NaF, 1 mM Na3VO4, 1 mM phenylmethanesulfonyl
fluoride, 1 mg/ml aprotinin, 50 mg/ml pepstatin, 500 mg/ml
leupeptin. Lysates were cleared by centrifugation at
13 000 g for 15 min at 48C and the protein concentration
in the supernatant was determined using the micro BCA
Protein Assay Reagent Kit (Pierce, Rockford, IL, USA).
The epitope-tagged MAPK/Erk 2 or JNK were immuno-
precipitated from aliquots (800 mg) of cell protein by
incubation with the anti-HA specific monoclonal antibody
12CA5 (BABCO) and protein G Sepharose (Pharmacia) for
2 h at 48C with stirring. Immunocomplexes were washed
three times with PBS containing 1% NP-40 and 2 mM
Na3VO4 once with 100 mM Tris-HCl (pH 7.5), 0.5 M LiCl
and once with kinase reaction buer (12.5 mM MOPS pH
7.5, 12.5 mM b-glycerophosphate, 7.5 mM MgCl2, 0.5 mM
EGTA, 0.5 mM NaF, 0.5 mM Na3VO4). The MAPK or
JNK activity was determined by resuspending the
immunoprecipitates in 30 ml of kinase reaction buer
containing 20 mM of unlabelled ATP, 1 mCi of [g-32P]ATP
and, as substrate, 10 mg of myelin basic protein for the
MAPK assay of 2 mg of GST-c-Jun (1 – 79) fusion protein
for the JNK assay (Coso et al., 1995). After 30 min at
308C, the reactions were stopped by adding of Laemmli’s
buer and boiled for 5 min under reducing conditions. The
samples were analysed by SDS electrophoresis on 12%
polyacrylamide gels. Phosphorylated substrates were
detected by autoradiography and quantitated using a
phosphoimager (Molecular Dynamics). The values of fold
increase were reported relative to MAPK/Erk 2-HA or
JNK-HA protein contents of the immunocomplexes, by
Western blotting with the anti-HA specific monoclonal
antibody 12CA5 and densitometer analysis.
In vivo tumorigenesis and lung colonization assays
To avoid clonal variations, in our analyses we used pooled
populations stable transfected NIH3T3 cells described
above, rather than isolated and specific clones for the
dierent biological assays. All cells were trypsinized,
neutralized with growth media and resuspended in 0.1 ml
of serum-free medium (DMEM, GIBCO –BRL Life
Technologies, Inc., Gaithersburg, MD) prior to injection.
In the tumorigenic assay the cells were subcutaneously
inoculated into the posterior flank of athymic nude mice.
The tumour formation was monitored weekly. Latency was
expressed as the period of time required by tumours to
reach a diameter of 15 – 20 mm. The animals, in which
tumours were not formed, were observed for 8 weeks. For
the experimental lung metastasis assay cells were injected
intravenously into the tail vein of athymic nu/nu mice. To
examine the presence of lung tumour masses the animals
were sacrificed when they appeared distressed or after 12
weeks from injection. For histological examinations the
lungs of tested mice were immersion fixed in formalin,
embedded in paran and sectioned at 5 mm. The sections
were stained with hematoxylin/eosin and evaluated by light
microscopy for identification of tumours.
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